Cate Spears

CGT Global was founded in 2010 to accelerate the cure and prevention of significant medical conditions at life-changing speed. CGT Global supports cell and gene therapies, commercialization of disease-specific treatments, medical research, clinical trials, precision/regenerative medicine, among other researchers and clinicians around the world who are developing and implementing revolutionary treatments and cures. CGT Global is currently the nation's leading biospecimen provider of human primary cells, stem cells, human bone marrow, cord blood, peripheral blood, maternal blood, and disease-state products for academic, biotechnological, diagnostic, pharmaceutical and contract research organizations. CGT Global is registered with the U.S. Food and Drug Administration (FDA) and has four (4) independently owned and operated brick-and mortar locations across the United States to collect blood, cells, and tissue from patients and donors. These clinics include state-of-the-art cell manufacturing laboratories for clinical and research purposes, and CLIA certified/high-complexity diagnostics. #celltherapy #genetherapy #primarycells #immunotherapy #immunology #cancerresearch #biotechnology #biospecimens #cancerresearch #biomedicalresearch #stemcellresearch #covidtesting